- Management to comment on SQI's commercial
progress and opportunities -
TORONTO, Aug. 18, 2014 /PRNewswire/ - SQI
Diagnostics Inc. (TSX-V: SQD), a life sciences company that
develops and commercializes proprietary technologies and products
for advanced microarray diagnostics, today announced it will hold
an investor conference call on Friday,
August 22 at 2:00 pm
ET.
During the call, Andrew Morris,
CEO, will provide a brief review of SQI's recent commercialization
progress and then introduce Dr. Allan
Pronovost, a diagnostics industry veteran recently appointed
to the Board of Directors of SQI and also as a Strategic Advisor to
the Board. Dr. Pronovost will comment on the Company and the
diagnostics industry from his perspective. The call will
conclude with Mr. Morris and Dr. Pronovost responding to any
questions from the investment community, which can be submitted
prior to the call by email to IR@sqidiagnostics.com.
To access the conference call, dial 647-427-7450 or
1-888-231-8191 or go to
http://www.newswire.ca/en/webcast/detail/1399518/1553736 or
www.sqidiagnostics.com. An archived replay of the webcast will be
available through www.sqidiagnostics.com.
About SQI Diagnostics
SQI Diagnostics is a life
sciences and diagnostics company that develops and commercializes
proprietary technologies and products for advanced microarray
diagnostics. The Company's proprietary microarray tests and
fully-automated systems are designed to simplify protein and
antibody testing workflow, increase throughput, reduce costs and
provide excellent data quality. For more information, please visit
www.sqidiagnostics.com.
Forward-looking Information
This news release
contains certain forward-looking statements, including, without
limitation, statements containing the words "will", "expects",
"intends" and other similar expressions which constitute
"forward-looking information" within the meaning of applicable
securities laws. Forward-looking statements reflect the Company's
current expectation and assumptions, and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to risks
related to the failure to obtain necessary regulatory approvals,
general economic and market segment conditions, and international
risk and currency exchange, agreements and future agreements to
sell our products, the success of our Diagnostic Tools and Services
business and our intent to build near-term revenue streams from
this business, the successful regulatory filing and receipt of
regulatory approvals for our later stage quantitative diagnostic
kits, the acceleration of our revenue ramp, general economic and
market segment conditions, competitor activity, technology changes
and regulatory approvals. Such statements reflect the current views
of the Company with respect to future events and are subject to
certain risks and uncertainties and other risks detailed from
time-to-time in the Company's ongoing filings with the securities
regulatory authorities, which filings can be found at
www.sedar.com. Actual results, events, and performance may differ
materially. Readers are cautioned not to place undue reliance on
these forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or
otherwise, except as required by applicable laws.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE SQI Diagnostics Inc.